We have used a proteomic approach using mass spectrometry to identify signaling molecules involved in receptor tyrosine kinase signaling pathways. Using affinity purification by anti-phosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins, we have identified a novel signaling molecule in the epidermal growth factor receptor signaling pathway. This molecule, designated Odin, contains several ankyrin repeats, two sterile alpha motifs and a phosphotyrosine binding domain and is ubiquitously expressed. Using antibodies against endogenous Odin, we show that it undergoes tyrosine phosphorylation upon addition of growth factors such as EGF or PDGF but not by cytokines such as IL-3 or erythropoietin. Immunofluorescence experiments as well as Western blot analysis on subcellular fractions demonstrated that Odin is localized to the cytoplasm both before and after growth factor treatment. Deletion analysis showed that the phosphotyrosine binding domain of Odin is not required for its tyrosine phosphorylation. Overexpression of Odin, but not an unrelated adapter protein, Grb2, inhibited EGF-induced activation of c-Fos promoter. Microinjection of wild-type or a mutant version lacking the PTB domain into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Taken together, our results indicate that Odin may play a negative role in growth factor receptor signaling pathways.
Introduction
EGF and PDGF receptors belong to one of the most intensively studied class of transmembrane moleculesthe family of receptor protein tyrosine kinases (Hunter and Cooper, 1985; Pawson, 1994; Ullrich and Schlessinger, 1990 ). Binding of ligand leads to homodimerization of the receptor subunits and activation of their catalytic domains followed by transphosphorylation of the receptors. This phosphorylation on tyrosine residues creates a distinct set of sites which trigger recruitment of signaling molecules with or without intrinsic catalytic activities (Pawson and Scott, 1997; van der Geer et al., 1994) .
We have recently begun a systematic study of signaling pathways by using affinity purification of lysates from growth factor stimulated cells using antiphosphotyrosine antibodies. Using this proteomic approach, we have reported identification of Vav-2 and STAM-2 as novel substrates of the EGFR and PDGFR pathways (Pandey et al., 2000a,b) . Here, we report the identification of a novel signaling molecule that contains six ankyrin repeats at its N terminus, two sterile alpha motifs (SAM), and a phosphotyrosine binding (PTB) domain at its C-terminus. We designate this molecule Odin after a deity in Nordic mythology.
Northern blotting shows that Odin is widely expressed as a single transcript of approximately 6 kb which is in agreement with the size of its cDNA. Immunoblotting using antibodies raised against Odin shows that it is expressed as an approximately 130 kDa protein. The small discrepancy between mRNA and protein levels may either be due to post-transcriptional regulation of Odin or because of the fact that we used mouse tissues for Western blot analysis whereas the Northern blot was performed on human mRNA samples. Odin is phosphorylated on tyrosine residues upon EGF or PDGF treatment but not with addition of cytokines such as IL-3 or erythropoietin. The PTB domain is not required for its tyrosine phosphorylation because Odin was still tyrosine phosphorylated upon deletion of the PTB domain. Immunofluorescence experiments demonstrate that Odin is localized to the cytoplasm both before and after addition of growth factors. The same results were observed when an antibody against Odin was used for Western blotting on subcellular fractions. Overexpression of Odin in 293 cells led to a decrease in EGFstimulated activation of a c-Fos promoter driven luciferase activity. Such an inhibition was not observed when Grb2, an adapter protein consisting of SH3 and SH2 domains, was similarly overexpressed. Microinjection of wild-type and DPTB Odin constructs into NIH3T3 fibroblasts inhibited PDGF-induced mitogenesis. Our results suggest that Odin is a signaling molecule that is capable of negatively regulating growth factor receptor signaling pathways.
Results and discussion
Identification of a novel signaling molecule, Odin, in the EGFR signaling pathway
In order to identify novel molecules involved in signal transduction pathways mediated by EGF, we used a strategy based on the ability of antiphosphotyrosine antibodies to enrich for tyrosine phosphorylated proteins as described earlier (Pandey et al., 2000a,b,c; Steen et al., 2002) . The band that was analysed in this study is indicated by an arrow in Figure 1a . The mass spectrum obtained from one of the tryptic peptides sequenced by nanoelectrospray tandem mass spectrometry (Wilm et al., 1996) is shown in Figure 1b . The peptide sequence derived from the fragmentation spectrum corresponded to a cDNA fragment (labeled KIAA0229 fragment) in the non-redundant nucleotide sequence database. Another tryptic peptide that was sequenced also matched the same protein and was derived from the N-terminus of this protein since it contained an acetylated glycine residue (data not shown). This served to establish that the cDNA that was designated as a fragment in the databases actually contained the entire open reading frame of this novel molecule. We have designated this molecule Odin after a deity in the Nordic mythology. The open reading frame of Odin encodes a protein of 1134 amino acid with a predicted molecular mass of approximately 123 kDa. Domain analysis of Odin sequence using SMART program revealed the presence of several modular domains ( Figure 1c ) (Schultz et al., 1998) . The region near the N-terminus contains six tandem ankyrin repeats that are found in several structural proteins (Sedgwick ) isolated from the band indicated in Figure 1a . The Y series of ions (C-terminus containing fragments) that are produced due to fragmentation are labeled as well as those from the B series (N-terminus containing fragments; b4, b5) according to convention (Biemann, 1988; Roepstorff and Fohlman, 1984) . The sequences of two peptide sequence tags that were used to search databases are shown. The complete peptide sequence that corresponds to this spectrum is shown at the top. Mox refers to an oxidized methionine residue. (c) The domain structure of Odin. The extent of the domains as predicted by the SMART program is indicated and Smerdon, 1999). It also contains two sterile alpha motif (SAM) domains that are found in several diverse signaling proteins and mediate protein-protein interactions (Ponting, 1995; Smalla et al., 1999) . At the Cterminus, Odin contains a PTB domain. PTB domains were initially discovered on the basis of their ability to bind to phosphotyrosine residues but have now been shown to bind to proteins in a phosphotyrosine independent fashion as well (Blaikie et al., 1994; Gustafson et al., 1995; Kavanaugh and Williams, 1994; Margolis, 1999; van der Geer et al., 1995) .
Odin is widely expressed in tissues and cell lines
In order to determine the expression of Odin in various tissues, a Northern blot analysis was performed. As shown in Figure 2a ,b, a single Odin transcript of approximately 6 kb was detected in almost all tissues and cell lines tested. This is in agreement with the isolated cDNA. In order to perform experiments with endogenous Odin, we have generated antibodies against peptides derived from its unique C terminus. Figure 2c shows that Odin is detected as a band of apparent molecular weight of approximately 130 kDa in lysates from all tissues tested. Figure 2d shows expression of Odin protein in Hela, 293T and HCD 57 cells. A similar sized band was seen in NIH3T3, 32D, BaF3 and TF-1 cells (data not shown). The observed molecular mass in these cell lines is in agreement with the predicted molecular mass of 123 kDa.
Odin is tyrosine phosphorylated by EGF or PDGF but not IL-3 or erythropoietin
To investigate the tyrosine phosphorylation status of Odin, we performed immunoprecipitation experiments in a variety of cell lines. Hela cells were left unstimulated or stimulated with EGF and the immunoprecipitated Odin was assessed for tyrosine phosphorylation by Western blotting with antiphosphotyrosine antibodies. As shown in Figure 3a , Odin is tyrosine phosphorylated when EGF is added. Odin is Figure 2 A human multiple tissue Northern blot (a) or a cancer cell line blot (b) (Clontech, Palo Alto, CA, USA) was probed with a 32 P-labeled cDNA probe according to the manufacturer's instructions (top panels). The bottom panels show reprobing of the blots with actin to confirm equal loading. Molecular mass markers in kb are indicated on the left. (c) Lysates from the indicated tissues were Western blotted using anti-Odin antibody that was generated against the C-terminus of Odin. (d) Lysates from the indicated cell lines were immunoprecipitated using preimmune or immune serum directed against Odin as indicated. The precipitated immune complexes were washed, subjected to SDS -PAGE, transferred onto nitrocellulose and Western blotted using anti-Odin antibody as shown similarly tyrosine phosphorylated upon PDGF stimulation in NIH3T3 fibroblasts (data not shown). However, we could not detect any tyrosine phosphorylation of Odin in response to cytokines such as erythropoietin in HCD57 cells (Figure 3b) . As a control, we could easily detect erythropoietin-induced tyrosine phosphorylation of JAK2 in these cells. Similarly, we could not detect any tyrosine phosphorylation of Odin in 32D cells in response to IL-3 although phosphorylation of JAK2 and Shc was easily detected (data not shown).
Localization of Odin to the cytoplasm
Since Odin contained putative nuclear localization signals predicted by PSORT program (Nakai and Kanehisa, 1992) , we wished to examine its subcellular localization in cells. By analogy to the STAT family of transcription factors which contain nuclear localization signals and SH2 domains (Darnell, 1997; Leonard and O'Shea, 1998) , it was conceivable that Odin upon tyrosine phosphorylation in response to ligand addition, might form dimers, and translocate to the nucleus. For this purpose, we generated a Flag-epitope tagged version of Odin and performed immunofluorescence experiments in NIH3T3 cells. As shown in Figure 4a , Odin was only localized to the cytoplasm and did not translocate to the nucleus when a time course experiment with PDGF was performed. Identical results were obtained when these studies were performed in Hela cells with EGF treatment or using anti-Odin antibody to detect endogenous Odin (data not shown). To elucidate further possible recruitment of Odin to the nucleus, we performed immunoblotting experiments on nuclear and cytosolic fractions prepared from Hela cells before or after EGF treatment. As Figure 4b clearly demonstrates, endogenous Odin was detected only in the cytosol under these conditions. Histone H3 and Shc served as a control in these experiments as typical nuclear and cytoplasmic proteins, respectively. These results confirm that contrary to predictions of nuclear localization by computer algorithms, Odin resides in the cytoplasm.
PTB domain of Odin is not required for its tyrosine phosphorylation
Since Odin contains a PTB domain and is tyrosine phosphorylated, we wished to determine whether the PTB domain is required for its tyrosine phosphorylation. To this end, we generated a mutant lacking the PTB domain as shown in Figure 5a . We have set up a reconstitution system in human embryonic kidney 293T cells. These cells have very low levels of endogenous EGFR and undetectable PDGFR. However, when a cDNA for EGFR or PDGFR is overexpressed by transfection and the ligand is added, the receptor signaling pathways are activated. Therefore, we transfected these cells with expression vectors for Odin or DPTB, in combination with cDNAs for EGFR or PDGFR. In each instance, EGF or PDGF was added to the cells after a period of serum starvation. As expected, the level of basal tyrosine phosphorylation in cells transfected with wild type Odin alone was minimal, although it was strongly upregulated upon (Figure 5a ). When a mutant lacking the PTB domain was tested, it underwent tyrosine phosphorylation similar to the wild type construct demonstrating that the presence of PTB domain was not necessary for its tyrosine phosphorylation.
Overexpression of Odin inhibits EGF-induced c-Fos activation and PDGF-induced mitogenesis
One of the earliest events in response to EGF stimulation in responsive cells is induction of immediate early genes such as c-Fos and c-Myc (Curran et al., 1985; Muller et al., 1984) . In order to examine the role of Odin in EGFR signal transduction pathway, we transfected a c-Fos promoter driven luciferase construct into 293 cells. Addition of EGF induced activation of this promoter in 293 cells (Figure 5b ). However, when Odin was overexpressed along with the reporter construct, it inhibited the induction of c-Fos luciferase promoter activity. This is in contrast to overexpression of another adapter protein Grb2 used as a control that induced slight activation of the c-Fos promoter. Microinjection of cDNAs has been used to investigate the role of a number of signaling molecules (Del Sal et al., 1992; Roche et al., 1995) . We decided to microinject wild-type Odin and DPTB cDNAs into NIH3T3 fibroblasts. As shown in Figure 5c , it was found that both constructs inhibited PDGF-induced mitogenesis in these cells. Microinjection of Shc, another molecule containing a PTB domain did not show this effect showing the specificity of this inhibition.
Conclusions
In this report we have isolated a novel adapter protein containing several ankyrin repeats, two SAM domains and a PTB domain. In spite of the presence of nuclear localization sequences and prediction for this protein to be nuclear, we have found it to be localized to the cytoplasm before and after growth factor stimulation. Cytosolic localization is also consistent with its biochemical purification from cytosolic and membrane fraction of Hela cell extracts as a tyrosine phosphorylated protein. PTB domains have now been found in a variety of proteins including Shc, IRS, Numb, Dab, p62Dok, and Jip-1 among others (Margolis, 1999) . In terms of sequence relatedness, these domains can be categorized into two classes: those that bear sequence homology to the PTB domain of Shc and those that are more similar to the PTB domain found in IRS molecules. The PTB domain of Odin is most related to that found in Numb (both of these are similar to the PTB domain of Shc). It is interesting to note that the binding of Numb PTB domain is phosphotyrosine independent but is critical for its ability to alter cell fate in Drosophila (Yaich et al., 1998) . Thus, Odin likely represents a cytosolic adapter protein that negatively regulates growth factor receptor signaling. Odin is likely to exert its effects further downstream in the growth factor receptor signaling pathways since we do not observe any association between Odin and the EGFR or PDGFR. This also suggests that the PTB domain of Odin may bind other tyrosine phosphorylated proteins or binds to proteins in a phosphotyrosine-independent fashion. In the last few years a number of studies appeared reporting scaffolding proteins, which in high concentrations inhibit distinct signaling pathways by keeping apart different players in these cascades (Burack and Shaw, 2000; Ito et al., 1999 ; Schaeffer et al., 1998; Whitmarsh et al., Figure 5 (a) Tyrosine phosphorylation of deletion mutants. 293T cells were transfected with the indicated expression vectors. Forty-eight hours after transfection the cells were serum-starved overnight and treated with EGF or PDGF to enhance tyrosine phosphorylation. Cell lysates were immunoprecipitated with anti-FLAG antibody followed by Western blotting with antiphosphotyrosine antibody as shown. The bottom panel shows reprobing of the blot by anti-FLAG antibody to confirm expression and equal loading. (b) Inhibition of EGF-induced c-Fos activation by overexpression of Odin. 293 cells were transfected with c-Fos luciferase construct along with b-galactosidase reporter plasmid and expression vectors for Odin or Grb2. Twenty-four hours after transfection the cells were split into two, allowed to recover for 12 h and then serum-starved overnight in the presence or absence of EGF. The luciferase and b-galactosidase activities were measured. Luciferase activities after normalization are shown in the figure. (c) Inhibition of PDGF induced mitogenesis in NIH3T3 fibroblasts by Odin. NIH3T3 fibroblasts were microinjected with the indicated expression vectors and BrdU incorporation was measured as an indicator of DNA synthesis 1998; Yasuda et al., 1999) . Future detailed analysis will be required to determine any possible scaffolding properties of Odin. Cloning of Odin will now allow the elucidation of the signaling mechanisms utilized by receptor tyrosine kinases in greater detail.
Materials and methods

Cell culture, growth factors and antibodies
Hela S3 cells were grown in Joklik's MEM with 5% fetal bovine serum, 2 g/l NaHCO 3 . NIH3T3 fibroblasts were grown in DMEM supplemented with 10% bovine calf serum and antibiotics. 293 cells were grown in DMEM supplemented with 10% fetal bovine serum and antibiotics. EGF, PDGF and anti-Histone H3 mAb were purchased from Upstate Biotechnology (Lake Placid, NY, USA). IL-3 and anti-Flag M2 mAb were from Sigma (St. Louis, MO, USA). Recombinant erythropoietin was a gift from AMGEN. AntiShc, anti-Jak2 and anti-Grb2 antibodies were from Transduction Labs. A KLH conjugated peptide corresponding to amino acids SVSWVVDPK PDSKRSLSTN was synthesized by Boston Biomolecules (Woburn, MA, USA).
cDNAs and constructs
The cDNA clone (KIAA0229) corresponding to Odin is one of the clones in the series of cDNA collection of the Kazusa DNA research institute (Nagase et al., 1996) . Wild type Odin was obtained by PCR and subcloned into the vector pCMVTag 4 (Stratagene, La Jolla, CA, USA). The D PTB mutant was obtained by subcloning a fragment from the wild type Odin construct into pCMV-Tag. Wild type EGFR was obtained by subcloning the EGFR cDNA (kindly provided by Dr Stuart Decker) into pcDNA3 vector. Wild type PDGFR beta cDNA (Kazlauskas and Cooper, 1989) was kindly provided by Dr Andrius Kazlauskas and was subcloned into pcDNA3. Grb2 cDNA was obtained from Dr Ste´phane Richard (Richard et al., 1995) .
Immunoprecipitation and Western blotting
For experiments shown in Figure 1 , a total of 5610 9 serumdeprived Hela S3 cells were left untreated or treated with 1 mg/ml of EGF for 5 min and the lysates processed as described previously (Pandey et al., 2000a) . For other experiments, 10 7 Hela or NIH3T3 cells were grown and starved as above and treated with EGF (100 ng/ml) or PDGF (50 ng/ml), respectively. In the case of BaF3 and HCD 57 cells, 10 8 cells were used per immunoprecipitation experiment. After transfer, the nitrocellulose membrane was blocked overnight at 48C and then incubated with the corresponding Western blotting antibody for 1 h. Affinity purified anti-Odin antibody was used at a concentration of 1 mg/ml. Incubation with secondary antibodies followed by detection was done according to manufacturer's instructions (ECL, Amersham Corp.).
Immunofluorescence NIH3T3 cells were transfected with a cDNA construct encoding Flag-tagged Odin and 8 h later seeded onto glass coverslips (Becton Dickinson, Sparks, MD, USA) and grown for additional 12 -16 h. The cells were serum starved for 20 to 24 h and left untreated or treated with PDGF for 5 or 30 min, fixed, and then permeabilized with 0.2% Triton X-100. Subsequently, cells were washed and incubated with anti-Flag M2 mAb followed by staining with TRITCconjugated anti-mouse antibody (DAKO, Denmark). Mounted slides were visualized on Leica DM RA fluorescence microscope (Leica Microsystems, Cambridge, UK).
Subcellular fractionation
Hela cells were first grown to 80% confluence in complete medium and then the medium replaced with serum free media. After 16 h, the cells were either untreated or treated with EGF for 30 min. Nuclear and cytoplasmic extracts from these cells were then prepared as described previously (Lavery and Schibler, 1993) with minor modifications. Briefly, cells were scraped in hypotonic buffer containing 20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl 2 , 1 mM DTE, 1 mM sodium orthovanadate and protease inhibitors. The samples were transferred to Dounce tissue grinder (Wheaton Science Products, Millville, NJ, USA) and cell membranes were broken by 30 strokes. The resulting suspension was centrifuged at 2000 r.p.m. for 5 min. The supernatant, containing the cytosolic proteins was carefully collected and nuclei were washed twice with hypotonic buffer. Purified nuclei were resuspended in 300 ml NUN-buffer, containing 27.6 mM HEPES, pH 7.6, 1.1 M urea, 330 mM NaCl, 1.1% NP-40, 1.1 mM DTE, 1 mM sodium orthovanadate and protease inhibitors. Total protein concentration was estimated by Bradford method and 50 mg from each cytosolic and nuclear faction were resolved by SDS -PAGE, followed by Western blotting with the indicated antibodies.
Northern blot analysis
Human multiple tissue and cancer cell line Northern blots (Clontech, Palo Alto, CA, USA) were probed according to the manufacturer's instructions using a 32 P-labeled 2.8-kb fragment derived from Odin cDNA.
Microinjection and luciferase assays
Microinjection assays were carried out as described previously (Manes et al., 2000) . For luciferase assays, 293 cells were grown to 60% confluence in complete medium and transfected with expression vectors in the following amounts: 1 mg of c-Fos luciferase, 0.1 mg of b-galactosidase and 3 mg of Odin-Flag, Grb2 or empty vector (see Figure 5b) . After 24 h, the cells were split into two and allowed to recover for 12 h. The cells were then serum-starved for 14 -16 h in the presence or absence of EGF (100 ng/ml). Cells were harvested and luciferase and b-galactosidase activities were measured on a MicroLumat luminometer (EG&G Berthold, Bad Wildbad, Germany).
Mass spectrometry
Identification of proteins by mass spectrometry was done essentially according to a strategy described previously (Shevchenko et al., 1996a) . The band indicated in Figure 1 was excised from one-dimensional silver-stained polyacrylamide gel and processed as described (Shevchenko et al., 1996b) . Digestion with trypsin (Boehringer Mannheim Biochemicals, Germany) was carried out for 4 h at 378C. The samples for MS/MS analysis were essentially prepared as described (Shevchenko et al., 1996a) . After in-gel digestion, 0.3 ml of supernatant (1 -3% of the total of about 30 ml) was removed for MALDI analysis and the rest loaded onto a Poros R2 TM (Perseptive Biosystems, Framingham, MA, USA) micro-cartridge, desalted, and eluted into nanoelectrospray needles (Protana, Odense, Denmark). Nanoelectrospray tandem mass spectrometry analysis (Wilm et al., 1996) was performed on a prototype of a quadrupoletime-of-flight mass spectrometer (QSTAR, Sciex, Toronto, Canada). The resulting 'peptide sequence tags' (Mann and Wilm, 1994) were used to search the nrdb database.
Abbreviations EGFR, epidermal growth factor receptor; MS/MS, tandem mass spectrometry; PTB, phosphotyrosine binding domain; SH2, src homology 2.
